Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

被引：15
|
作者：
Zhang, Jing [1 ]
Romero, Jan [1 ]
Chan, Audrey [1 ]
Goss, Jennifer [1 ]
Stucka, Sabrina [1 ]
Cross, Jason [1 ]
Chamberlain, Brian [1 ]
Varoglu, Mustafa [1 ]
Chandonnet, Haoqun [1 ]
Ryan, Dominic [1 ]
Lippa, Blaise [1 ]
机构：
[1] Cubist Pharmaceut, Lexington, MA 02421 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2015年 / 25卷 / 17期
关键词：
IBD; Crohn's disease; Ulcerative colitis; CCR9; Sulfonamide; CELLS; LOCALIZATION; LYMPHOCYTES; RECEPTOR;
D O I：
10.1016/j.bmcl.2015.06.046
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key chemokine receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码：3661 / 3664
页数：4
相关论文
共 50 条
  • [41] Kidney transplantation: does CCR9 play a role in rejection?
    Al-Hamidi, A
    Tyler, J
    Robertson, H
    Kirby, JA
    IMMUNOLOGY, 2005, 116 : 107 - 107
  • [42] Involvement of CCR9 at multiple stages of adult T lymphopoiesis
    Svensson, Marcus
    Marsal, Jan
    Uronen-Hansson, Heli
    Cheng, Min
    Jenkinson, William
    Cilio, Corrado
    Jacobsen, Sten Eirik W.
    Sitnicka, Ewa
    Anderson, Graham
    Agace, William W.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2008, 83 (01) : 156 - 164
  • [43] CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus
    Zlotoff, Daniel A.
    Sambandam, Arivazhagan
    Logan, Theodore D.
    Bell, J. Jeremiah
    Schwarz, Benjamin A.
    Bhandoola, Avinash
    BLOOD, 2010, 115 (10) : 1897 - 1905
  • [44] Inhibition of CCR9 as a therapeutic approach: beyond the small intestine
    Berahovich, R.
    Walters, M.
    Wang, Y.
    Wei, Z.
    Ungashe, S.
    Lai, N.
    Ertl, L.
    Baumgart, T.
    Howard, M.
    Jaen, J.
    Schall, T.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (01) : S31 - S31
  • [45] In-silico guided discovery of novel CCR9 antagonists
    Xin Zhang
    Jason B. Cross
    Jan Romero
    Alexander Heifetz
    Eric Humphries
    Katie Hall
    Yuchuan Wu
    Sabrina Stucka
    Jing Zhang
    Haoqun Chandonnet
    Blaise Lippa
    M. Dominic Ryan
    J. Christian Baber
    Journal of Computer-Aided Molecular Design, 2018, 32 : 573 - 582
  • [46] Potential role of CCR9 in gastrointestinal involvement of ATL cells
    Nagakubo, Daisuke
    Jin, Zhe
    Hieshima, Kunio
    Nakayama, Takashi
    Shirakawa, Aiko-Konno
    Yoshie, Osamu
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [47] Ccr9 expression defines the maturation level of dendritic cells
    Drakes, Maureen
    Blanchard, Thomas G.
    GASTROENTEROLOGY, 2007, 132 (04) : A555 - A555
  • [48] AZD7798: A NEW CCR9 DEPLETING ANTIBODY TO TREAT CROHN'S DISEASE
    Nys, Josquin
    Thom, George
    Cariuk, Peter
    Riley, Aidan
    Kelly, Aoife
    Swieboda, Dawid P.
    Huntington, Catherine
    Rees, D. G.
    Irving, Lorraine M.
    Schofield, Darren
    Daramola, Lekan
    Stebbings, Richard
    Marks, Daniel J.
    GASTROENTEROLOGY, 2023, 164 (06) : S674 - S674
  • [49] Functional CCR9 expression is associated with small intestinal metastasis
    Letsch, A
    Keilholz, U
    Schadendorf, D
    Assfalg, G
    Asemissen, AM
    Thiel, E
    Scheibenbogen, C
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : 685 - 690
  • [50] CCR9 as a prognostic marker and therapeutic target in hepatocellular carcinoma
    Zhang, Zhenhai
    Qin, Chengkun
    Wu, Yaguang
    Su, Zhongxue
    Xian, Guozhe
    Hu, Bo
    ONCOLOGY REPORTS, 2014, 31 (04) : 1629 - 1636
12345